Cite
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
MLA
Sakai, Ryoko, et al. “Head-to-Head Comparison of the Safety of Tocilizumab and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients (RA) in Clinical Practice: Results from the Registry of Japanese RA Patients on Biologics for Long-Term Safety (REAL) Registry.” Arthritis Research & Therapy, vol. 17, Mar. 2015, p. 74. EBSCOhost, https://doi.org/10.1186/s13075-015-0583-8.
APA
Sakai, R., Cho, S.-K., Nanki, T., Watanabe, K., Yamazaki, H., Tanaka, M., Koike, R., Tanaka, Y., Saito, K., Hirata, S., Amano, K., Nagasawa, H., Sumida, T., Hayashi, T., Sugihara, T., Dobashi, H., Yasuda, S., Sawada, T., Ezawa, K., … Harigai, M. (2015). Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Research & Therapy, 17, 74. https://doi.org/10.1186/s13075-015-0583-8
Chicago
Sakai, Ryoko, Soo-Kyung Cho, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, et al. 2015. “Head-to-Head Comparison of the Safety of Tocilizumab and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients (RA) in Clinical Practice: Results from the Registry of Japanese RA Patients on Biologics for Long-Term Safety (REAL) Registry.” Arthritis Research & Therapy 17 (March): 74. doi:10.1186/s13075-015-0583-8.